Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - Entrada Therapeutics ( NASDAQ:TRDA ) , Biogen ( NASDAQ:BIIB )
BOSTON, June 03, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
NIRI Twin Cities Chapter Elects 2025-2026 Board of Directors
MINNEAPOLIS, June 03, 2025 ( GLOBE NEWSWIRE ) -- The Twin Cities Chapter ( www.niri-twincities.org ) of the National Investor Relations Institute ( NIRI ) today announced the election of its officers and directors for the 2025-2026 program year, which begins July 1, 2025.
VEON and Engro Corporation Complete Pioneering Infrastructure Partnership in Pakistan - VEON ( NASDAQ:VEON )
Islamabad and Dubai, June 3, 2025: VEON Ltd. VEON, a global digital operator ( "VEON" or "the Company" ) , announces that it has successfully closed the partnership for the pooling and management of telecommunications infrastructure assets in Pakistan with Engro Corporation Limited ( "Engro Corp" ...
Guardian Capital LP Launches New GuardBonds™ Funds
TORONTO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Guardian Capital LP ( "Guardian Capital" ) is excited to announce the launch of GuardBonds™ 2028 Investment Grade Bond Fund GBFE and GuardBonds™ 2029 Investment Grade Bond Fund GBFF ( the "New GuardBonds™ Funds ) to join the existing suite of ...
BioStem Technologies Provides Update on the Company's Form 10 Submission and SEC Review Process - BioStem Technologies ( OTC:BSEM )
POMPANO BEACH, Fla., June 03, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( "BioStem" or the "Company" ) BSEM, a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on ...
Fury Announces 2025 Exploration Plans at Committee Bay
TORONTO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Fury Gold Mines Limited ( TSX and NYSE American: FURY ) ( "Fury" or the "Company" ) is pleased to provide an update on exploration plans for the Committee Bay project, located in the eastern Kitikmeot region of Nunavut, Canada.
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
FLORHAM PARK, N.J., June 03, 2025 ( GLOBE NEWSWIRE ) -- BeyondSpring Inc. ( NASDAQ: BYSI ) ( "BeyondSpring" or the "Company" ) , a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a ...
